指南与共识血脂与心血管预防冠心病

指南推荐在年轻成人心肌梗死预防中的表现

Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults.
指南 / 共识 · J Am Coll Cardiol · 2020-01-01

该研究基于杜克大学医学中心首次心肌梗死患者数据,评估2013与2018 AHA/ACC胆固醇指南对他汀一级预防及强化二级预防资格识别的影响。结果显示2018指南在年轻患者心梗时识别出的他汀合格比例低于2013指南(46.4% vs 56.7%),且多数年轻早发心梗患者未被推荐强化降脂。

要点

  • 2018指南使年轻心梗患者他汀一级预防资格识别率低于2013指南。
  • 年轻患者较中年和老年更少符合强化二级预防降脂的极高危标准。
  • 极高危标准与年轻患者主要不良心血管事件风险升高相关。

核心结论

  • 基于2018指南,多数年轻早发心梗患者在事件前未被识别为他汀候选者。
  • 多数早发心梗患者未获推荐进行梗死后强化降脂管理。

研究设计与样本

  • 研究纳入杜克大学医学中心首次心肌梗死成人患者,共6639例。
  • 按2013 ACC/AHA与2018 AHA/ACC指南标准判定他汀治疗资格。
  • 评估2018指南下极高危强化降脂潜在资格及复合终点事件率。

主要发现

  • 年轻(<55岁)患者吸烟(52%)、肥胖(42%)、代谢综合征(21%)比例及LDL-C水平(117 mg/dl)均高于中年和老年组(趋势P<0.01)。
  • 心梗前,年轻患者符合他汀指南指征的比例低于中年和老年患者。
  • 心梗时2018指南识别他汀合格的年轻患者比例低于2013指南(46.4% vs 56.7%;P<0.01)。
  • 年轻患者符合极高危强化二级预防降脂标准的比例低于中年和老年(28.3% vs 40.0% vs 81.4%;P<0.01)。
  • 中位随访8年,极高危标准与<55岁患者主要不良心血管事件风险升高相关(HR 2.09;95%CI 1.82-2.41;P<0.001),各年龄组间无交互作用(P interaction=0.54)。

关键数值与推荐

  • 他汀合格判定依据2013 ACC/AHA与2018 AHA/ACC胆固醇指南标准。
  • 极高危强化降脂潜在资格依据2018 AHA/ACC指南标准评估。

临床怎么用

  • 对年轻早发心梗患者,应关注2018指南可能低估其事件前他汀预防资格。
  • 年轻心梗后患者多数不符合极高危标准,需评估是否应强化降脂管理。
  • 极高危标准可用于识别年轻心梗后主要不良心血管事件高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2018 cholesterol guidelines of the American Heart Association and the American College of Cardiology (AHA/ACC) changed 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) eligibility criteria for primary prevention to include multiple risk enhancers and novel intensive lipid-lowering therapies for secondary prevention. OBJECTIVES: This study sought to determine how guideline changes affected identification for preventive therapy in young adults with premature myocardial infarction (MI). METHODS: The study identified adults presenting with first MI at Duke University Medical Center in Durham, North Carolina. Statin therapy eligibility was determined using the 2013 ACC/AHA and 2018 AHA/ACC guidelines criteria. The study also determined potential eligibility for intensive lipid-lowering therapies (very high risk) under the 2018 AHA/ACC guidelines, by assessing the composite of all-cause death, recurrent MI, or stroke rates in adults considered "very high risk" versus not. RESULTS: Among 6,639 patients with MI, 41% were <55 years of age ("younger"), 35% were 55 to 65 years of age ("middle-aged"), and 24% were 66 to 75 years of age ("older"). Younger adults were more frequently smokers (52% vs. 38% vs. 22%, respectively) and obese (42% vs. 34% vs. 31%, respectively), with metabolic syndrome (21% vs. 19% vs. 17%, respectively) and higher low-density lipoprotein cholesterol (117 vs. 107 vs. 103 mg/dl, respectively) (p trend <0.01 for all). Pre-MI, fewer younger adults met guideline indications for 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) therapy than middle-aged and older adults. The 2018 guideline identified fewer younger adults eligible for statin therapy at the time of their MI than the 2013 guideline (46.4% vs. 56.7%; p < 0.01). Younger patients less frequently met very high-risk criteria for intensive secondary prevention lipid-lowering therapy (28.3% vs. 40.0% vs. 81.4%, respectively; p < 0.01). Over a median 8 years of follow-up, very high-risk criteria were associated with increased risk of major adverse cardiovascular events in individuals <55 years of age (hazard ratio: 2.09; 95% confidence interval: 1.82 to 2.41; p < 0.001), as was the case in older age groups (p interaction = 0.54). CONCLUSIONS: Most younger patients with premature MI are not identified as statin candidates before their event on the basis of the 2018 guidelines, and most patients with premature MI are not recommended for intensive post-MI lipid management.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zeitouni M, Nanna MG, Sun JL, et al. Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. J Am Coll Cardiol. 2020. PMID: 32762899. doi:10.1016/j.jacc.2020.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。